This page is part of the Clinical Guidelines (v2.0.0-ballot: STU2 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. The current version which supersedes this version is 1.0.0. For a full list of available versions, see the Directory of published versions
Active as of 2023-12-19 |
Generated Narrative: PlanDefinition
Resource PlanDefinition "chf-lasix"
Profile: CPG Recommendation Definition
CQF Knowledge capability: shareable
CQF Knowledge capability: computable
CQF Knowledge capability: publishable
CQF knowledge representation level: structured
CPG Part Of Extension: CHFHypervolemia
CPG Enabled Extension: true
StructureDefinition Work Group: cds
url: http://hl7.org/fhir/uv/cpg/PlanDefinition/chf-lasix
version: 2.0.0-ballot
name: CHFLASIX
type: ECA Rule (PlanDefinitionType#eca-rule)
status: active
experimental: true
date: 2023-12-19 19:53:17+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description: Administer LASIX IV, transition to PO as appropriate
jurisdiction: World (m49.htm#001)
Description | Start |
Transition to LASIX PO () | Admission to hospital (SNOMED CT#32485007) |
action
id
lasix-ivtitle: LASIX IV
description: Administer LASIX IV
code: Dispense Medications (CPG Common Process Code System#dispense-medications)
condition
kind: stop
Expressions
Language Expression text/cql-identifier Should Stop LASIX IV definition: CHFLASIXIV
action
id
lasix-potitle: LASIX PO
description: Administer LASIX PO
code: Dispense Medications (CPG Common Process Code System#dispense-medications)
condition
kind: start
Expressions
Language Expression text/cql-identifier Should Start LASIX PO definition: CHFLASIXPO